PCSA Processa Pharmaceuticals Inc

Price (delayed)

$1.73

Market cap

$4.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.39

Enterprise value

-$3.84M

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a ...

Highlights
The EPS has soared by 81% YoY and by 25% from the previous quarter
Processa Pharmaceuticals's quick ratio has surged by 78% YoY and by 37% QoQ
Processa Pharmaceuticals's equity has surged by 78% QoQ but it has decreased by 12% YoY

Key stats

What are the main financial stats of PCSA
Market
Shares outstanding
2.86M
Market cap
$4.94M
Enterprise value
-$3.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.83M
EBITDA
-$9.74M
Free cash flow
-$8M
Per share
EPS
-$6.39
Free cash flow per share
-$3.24
Book value per share
$3.11
Revenue per share
$0
TBVPS
$4.03
Balance sheet
Total assets
$9.94M
Total liabilities
$1.06M
Debt
$140,380
Equity
$8.88M
Working capital
$8.79M
Liquidity
Debt to equity
0.02
Current ratio
9.7
Quick ratio
8.85
Net debt/EBITDA
0.9
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-115.9%
Return on equity
-130.1%
Return on invested capital
-1,960.2%
Return on capital employed
-110%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCSA stock price

How has the Processa Pharmaceuticals stock price performed over time
Intraday
-3.89%
1 week
4.22%
1 month
-1.14%
1 year
-81.32%
YTD
-74.15%
QTD
-23.11%

Financial performance

How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.98M
Net income
-$9.83M
Gross margin
N/A
Net margin
N/A
Processa Pharmaceuticals's operating income has surged by 65% YoY and by 13% QoQ
PCSA's net income has soared by 65% YoY and by 12% QoQ

Growth

What is Processa Pharmaceuticals's growth rate over time

Valuation

What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 81% YoY and by 25% from the previous quarter
PCSA's P/B is 87% below its 5-year quarterly average of 4.5 and 52% below its last 4 quarters average of 1.2
Processa Pharmaceuticals's equity has surged by 78% QoQ but it has decreased by 12% YoY

Efficiency

How efficient is Processa Pharmaceuticals business performance
Processa Pharmaceuticals's return on invested capital has surged by 55% YoY and by 30% QoQ
The ROA has grown by 37% YoY and by 5% from the previous quarter
Processa Pharmaceuticals's return on equity has increased by 37% YoY and by 8% QoQ

Dividends

What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCSA.

Financial health

How did Processa Pharmaceuticals financials performed over time
Processa Pharmaceuticals's quick ratio has surged by 78% YoY and by 37% QoQ
Processa Pharmaceuticals's total assets has surged by 72% QoQ but it has decreased by 20% YoY
PCSA's debt is 98% smaller than its equity
Processa Pharmaceuticals's equity has surged by 78% QoQ but it has decreased by 12% YoY
PCSA's debt is down by 33% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.